[HTML][HTML] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …
Preliminary experience with dosimetry, response and patient reported outcome after Lu-177-PSMA-617 therapy for metastatic castration-resistant prostate cancer
WP Fendler, S Reinhardt, H Ilhan, A Delker… - …, 2017 - epub.ub.uni-muenchen.de
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of Lu-177-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of Lu-177-PSMA-617 …
[PDF][PDF] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Age - researchgate.net
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Oncotarget, 2017 - europepmc.org
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
WP Fendler, S Reinhardt, H Ilhan, A Delker… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
[HTML][HTML] Preliminary experience with dosimetry, response and patient reported outcome after 177 Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Oncotarget, 2016 - oncotarget.com
Preliminary experience with dosimetry, response and patient reported outcome after 177 Lu-PSMA-617
therapy for metastatic castration-resistant prostate cancer | Oncotarget Online ISSN: 1949-2553 …
therapy for metastatic castration-resistant prostate cancer | Oncotarget Online ISSN: 1949-2553 …
[PDF][PDF] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Age - pdfs.semanticscholar.org
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
[引用][C] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Oncotarget, 2016 - cir.nii.ac.jp
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617
therapy for metastatic castration-resistant prostate cancer | CiNii Research CiNii 国立情報学 …
therapy for metastatic castration-resistant prostate cancer | CiNii Research CiNii 国立情報学 …
[PDF][PDF] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Age - core.ac.uk
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
[PDF][PDF] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Age - researchgate.net
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 …